研究II期试验设计中的异质性可能会提高III期试验的成功率。 - Suppr

Suppr

超能文献

Examining heterogeneity in phase II trial designs may improve success in phase III.

作者信息

Tuma Rabiya S

出版信息

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29.

DOI:10.1093/jnci/djn006

PMID:18230788

Abstract

摘要

相似文献

Examining heterogeneity in phase II trial designs may improve success in phase III.

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29.

Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057.

Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9. doi: 10.1158/1078-0432.CCR-05-1136.

Optimising the design of phase II oncology trials: the importance of randomisation.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

Newer phase II trial designs gaining ground.

J Natl Cancer Inst. 2007 Oct 3;99(19):1428-9. doi: 10.1093/jnci/djm182. Epub 2007 Sep 25.

Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

J Clin Oncol. 2008 Dec 20;26(36):5845-8. doi: 10.1200/JCO.2008.19.7996. Epub 2008 Nov 24.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

引用本文的文献

Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.

PLoS One. 2017 Dec 7;12(12):e0185536. doi: 10.1371/journal.pone.0185536. eCollection 2017.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Examining heterogeneity in phase II trial designs may improve success in phase III.

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29.

Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057.

Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9. doi: 10.1158/1078-0432.CCR-05-1136.

Optimising the design of phase II oncology trials: the importance of randomisation.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

Newer phase II trial designs gaining ground.

J Natl Cancer Inst. 2007 Oct 3;99(19):1428-9. doi: 10.1093/jnci/djm182. Epub 2007 Sep 25.

Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

J Clin Oncol. 2008 Dec 20;26(36):5845-8. doi: 10.1200/JCO.2008.19.7996. Epub 2008 Nov 24.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

引用本文的文献

Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.

PLoS One. 2017 Dec 7;12(12):e0185536. doi: 10.1371/journal.pone.0185536. eCollection 2017.